{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:55:35Z","timestamp":1780592135284,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.pupt.2018.12.003","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T23:00:34Z","timestamp":1546038034000},"page":"87-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life"],"prefix":"10.1016","volume":"54","author":[{"given":"Carlo","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3661-5731","authenticated-orcid":false,"given":"Diego","family":"Bagnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Caruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"D'Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Milanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianenrico","family":"Senna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Walter","family":"Canonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Passalacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2018.12.003_bib1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2018.12.003_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12890-016-0290-5","article-title":"Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience","volume":"16","author":"Caminati","year":"2016","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.pupt.2018.12.003_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12890-018-0689-2","article-title":"Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response","volume":"18","author":"Drick","year":"2018","journal-title":"BMC Pulm. Med."},{"issue":"1","key":"10.1016\/j.pupt.2018.12.003_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40413-018-0210-7","article-title":"Anti-IL-5 therapy in real life. The North-Western Italian experience 3 and comparison with the regulatory trials","volume":"11","author":"Bagnasco","year":"2018","journal-title":"World Allergy Organ. J."},{"key":"10.1016\/j.pupt.2018.12.003_bib5","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2018.12.003_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.12.003_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.pupt.2018.12.003_bib8","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.pupt.2018.12.003_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.pupt.2018.12.003_bib10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2018.12.003_bib11","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14740338.2016.1186641","article-title":"The safety of monoclonal antibodies in asthma","volume":"15","author":"Passalacqua","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.pupt.2018.12.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","author":"Khatri","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2018.12.003_bib13","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553918302773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T14:48:35Z","timestamp":1547563715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553918302773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":13,"alternative-id":["S1094553918302773"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.12.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}